Clinical Trial: Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
Study Status: Completed
Recruit Status: RECRUITING
Condition: Brain Metastases
Study Type: INTERVENTIONAL
Official Title: Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
Brief Summary:
To learn if the combination of niraparib and dostarlimab can help to control advanced cancer that has spread to the brain.
Read more